Prescribing Information

 

ALECENSA®▼(alectinib)

Avastin® (bevacizumab)

Esbriet® (pirfenidone)

GAZYVARO® (obinutuzumab)

HEMLIBRA®▼(emicizumab)

Herceptin® (trastuzumab) IV

Herceptin® (trastuzumab) SC

Kadcyla® (trastuzumab emtansine)

OCREVUS®▼ (ocrelizumab)

Perjeta® (pertuzumab)

RoACTEMRA® (tocilizumab) RA/GCA

RoACTEMRA® (tocilizumab) pJIA/sJIA

Tecentriq®▼  (atezolizumab) NSCLC

Tecentriq®▼  (atezolizumab) mTNBC

 

 

IV, intravenous; SC, subcutaneous; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; RA, rheumatoid arthritis; GCA, giant cell arteritis; pJIA, juvenile idiopathic polyarthritis; sJIA, systemic juvenile idiopathic arthritis; NSCLC, Non-small-cell lung carcinoma; UC, urothelial carcinoma; mTNBC, metastatic triple-negative breast cancer

 

For the Summary of Product Characteristics for all Roche products available in the UK please see www.medicines.org.uk/emc.

 

 

RXUKNONP00462(8)

Date of preparation: October 2019